US Patent

US9987285 — High dosage strength tablets of rucaparib

Formulation · Assigned to Clovis Oncology Inc · Expires 2035-08-17 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a tablet formulation of high dosage rucaparib camsylate salt.

USPTO Abstract

A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed.

Drugs covered by this patent

rucaparib-camsylate (RUCAPARIB CAMSYLATE)

Patent Metadata

Patent number: US9987285
Jurisdiction: US
Classification: Formulation
Expires: 2035-08-17
Drug substance claim: No
Drug product claim: Yes
Assignee: Clovis Oncology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.